Applications of Technology in Emerging Markets

Session 504
Emerging Markets Track

Pharma in the West is facing productivity problems. One option to overcome that challenge is getting active in emerging markets by either outsourcing to CRO's /CMO's in those countries, by partnering with companies in those countries or by setting up your own capacities there. In particular are India and China the places to go for pharma?

Session Description

The centre of global pharmaceutical industry is shifting. So the topic will focus on chemical and pharmaceutical research and development in Asia. In particular,

reasons, drivers and necessity for Big Pharma to go East
selection of the right partners in India, China and Singapore
importance and benefits of off-shoring for clinical R&D
intellectual property risks in Asia
different organizational models
cross-cultural aspects to consider when doing business in Asia

The importance of off-shoring goes far beyond cost saving. Today it is about shortening cycle times, tapping into talent pools in India and China, penetrating new emerging huge markets and developing products for local markets in close proximity to customers.

In summary, off-shoring of chemical and pharmaceutical R&D represents a powerful tool to cope with the current productivity challenges in multinational Big Pharma.

At the conclusion of this session, participants will:

Learn about status quo, benefits, insights, opportunities and risks of Pharma R&D off-shoring.
Get to know India and China pharma market and domestic industry.
Get insights into Intellectual property situation in Asian countries.
Learn about off-shoring operating models and their pros & cons.

Leaders

Speakers

Jeff Campie, USA
Richard Forsyth, Senior Consultant, Hyde Engineering + Consulting, USA
Nigel Hamilton, Global Quality, Strategy and Process Excellence, Sanofi Aventis, United Kingdom
Aisling Horan, Validation Scientist, Alkermes Plc, Ireland
Edwin Melendez, Principle Consultant, Parexel, USA
Mark O'Reilly, Director Engineering, Alkermes Pharma Ireland Ltd, Ireland
Kimberly Ray, A. Director Project Mgmt, Oso Biopharmaceuticals Mfg LLC, USA
Julian Wilkins, Vice President, PharmaConsult US Inc, USA
Paul Wreglesworth, Independent Consultant, United Kingdom